CL2018000299A1 - Composiciones con potenciadores de impregnacion para el suministro de fármacos. - Google Patents

Composiciones con potenciadores de impregnacion para el suministro de fármacos.

Info

Publication number
CL2018000299A1
CL2018000299A1 CL2018000299A CL2018000299A CL2018000299A1 CL 2018000299 A1 CL2018000299 A1 CL 2018000299A1 CL 2018000299 A CL2018000299 A CL 2018000299A CL 2018000299 A CL2018000299 A CL 2018000299A CL 2018000299 A1 CL2018000299 A1 CL 2018000299A1
Authority
CL
Chile
Prior art keywords
enhancers
impregnation
compositions
drug delivery
agent
Prior art date
Application number
CL2018000299A
Other languages
English (en)
Inventor
Daniel S Kohane
Rong Yang
Lily Yun Lin
Original Assignee
Childrens Medical Center
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Massachusetts Inst Technology filed Critical Childrens Medical Center
Publication of CL2018000299A1 publication Critical patent/CL2018000299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
    • C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
    • C08G65/3355—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus having phosphorus bound to carbon and oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/04—Phosphorus linked to oxygen or to oxygen and carbon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN AGENTE TERAPÉUTICO, B) UN POTENCIADOR DE PERMIACION O COMBINACIÓN, Y C) UN AGENTE FORMADOR DE MATRIZ O COMBINACIÓN DE AGENTES, QUE SE PREPARA EN CONDICIONES DETERMINADAS.</p>
CL2018000299A 2015-08-05 2018-02-01 Composiciones con potenciadores de impregnacion para el suministro de fármacos. CL2018000299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201199P 2015-08-05 2015-08-05

Publications (1)

Publication Number Publication Date
CL2018000299A1 true CL2018000299A1 (es) 2018-07-06

Family

ID=57943671

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000299A CL2018000299A1 (es) 2015-08-05 2018-02-01 Composiciones con potenciadores de impregnacion para el suministro de fármacos.

Country Status (21)

Country Link
US (2) US11110175B2 (es)
EP (1) EP3331547A4 (es)
JP (2) JP7046793B2 (es)
KR (1) KR20180030416A (es)
CN (1) CN108135967B (es)
AU (1) AU2016304585B2 (es)
BR (1) BR112018002227A2 (es)
CA (1) CA2994702A1 (es)
CL (1) CL2018000299A1 (es)
CO (1) CO2018001407A2 (es)
CR (1) CR20180128A (es)
EA (1) EA201890458A1 (es)
EC (1) ECSP18017254A (es)
HK (1) HK1252531A1 (es)
IL (1) IL257329A (es)
MA (1) MA43574A (es)
MX (1) MX2018001571A (es)
PE (1) PE20181153A1 (es)
PH (1) PH12018500262A1 (es)
WO (1) WO2017024282A1 (es)
ZA (1) ZA201800960B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331547A4 (en) 2015-08-05 2019-08-21 Children's Medical Center Corporation COMPOSITIONS WITH PERMEATION PROMOTERS FOR ACTIVE INJECTION
WO2017166173A1 (en) * 2016-03-31 2017-10-05 Dow Global Technologies Llc Method of making hydrophobic silica particles
EP3512501A4 (en) * 2016-09-14 2020-04-29 Children's Medical Center Corporation COMPOSITIONS WITH PERMEATION AMPLIFIERS FOR MEDICATION RELEASE
US11173210B2 (en) * 2017-10-24 2021-11-16 Sonoran Biosciences, Inc. Temperature-responsive degradable hydrogels
WO2019157370A1 (en) 2018-02-09 2019-08-15 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
CA3110566A1 (en) * 2018-08-31 2020-03-05 Children's Medical Center Corporation Compositions with synergistic permeation enhancers for drug delivery
US20220008336A1 (en) * 2018-11-26 2022-01-13 Aiviva Biopharma, Inc. Pharmaceutical biodissolvable gels for drug delivery
CN109513036B (zh) * 2019-01-11 2021-04-20 四川大学 一种受体温诱导可自动关闭抗菌功能的胶原蛋白材料
CN110028624A (zh) * 2019-04-16 2019-07-19 昆明理工大学 基于半纤维素复合温敏凝胶的制备方法及应用
EP3962533A4 (en) * 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
EP4182377A1 (en) * 2020-07-16 2023-05-24 3M Innovative Properties Company Phosphate-containing copolymers for virulence suppression
US20230270749A1 (en) * 2020-08-03 2023-08-31 Children's Medical Center Corporation Thermo-sensitive permeation enhancing formulations for drug delivery
CN111849597B (zh) * 2020-08-04 2022-08-09 中山华明泰科技股份有限公司 一种烷烃煤基油合成润滑剂的制备方法和应用
WO2022055927A1 (en) * 2020-09-11 2022-03-17 Ps Therapy Ltd. Topical compositions and methods of use
CN113304104A (zh) * 2021-05-11 2021-08-27 四川大学 一种智能温敏型缓释凝胶及其制备方法
WO2022256291A1 (en) * 2021-06-01 2022-12-08 President And Fellows Of Harvard College Hydrogel devices for drug delivery to the ear
EP4279061A1 (en) * 2022-05-18 2023-11-22 Acousia Therapeutics GmbH Aqueous gel composition
CN118078964B (zh) * 2024-04-24 2024-07-12 长春生物制品研究所有限责任公司 重组人干扰素软膏及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3798290A (en) * 1971-07-26 1974-03-19 Stauffer Chemical Co Mixed polyalkylene glycol polyphosphorus compound
FR2393586A1 (fr) 1977-06-08 1979-01-05 Roussel Uclaf Dispositif pour l'administration de substances medicamenteuses
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
EP0725628B1 (en) 1994-08-30 2001-11-07 Alcon Laboratories, Inc. Thermally-gelling drug delivery vehicles containing cellulose ethers
US6201065B1 (en) * 1995-07-28 2001-03-13 Focal, Inc. Multiblock biodegradable hydrogels for drug delivery and tissue treatment
US5684051A (en) 1996-04-24 1997-11-04 Hercules Incorporated Medical devices with improved elastic response
AU4990797A (en) 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US8197461B1 (en) * 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
ATE316786T1 (de) 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
ES2280524T3 (es) 2001-03-27 2007-09-16 Eli Lilly And Company Kit que incluye aguja de jeringuilla de disparo lateral para preparar un farmaco en un cartucho de pluma inyectora.
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
EP1651210A1 (en) * 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
JP2007513961A (ja) 2003-12-10 2007-05-31 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびその使用法
US9056061B2 (en) 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
US7547692B2 (en) 2005-12-14 2009-06-16 Activbiotics Pharma, Llc Rifamycin analogs and uses thereof
WO2007120818A2 (en) 2006-04-12 2007-10-25 Massachusetts Institute Of Technology Compositions and methods for inhibiting adhesions
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
EP2299976A4 (en) 2008-12-22 2014-07-23 Otonomy Inc SELF-CONTROLLED RELEASE SENSORY CELL MODULATOR COMPOSITIONS AND METHODS FOR TREATING OTIC DISORDERS
EP3508197A1 (en) 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
KR20150027684A (ko) * 2013-08-29 2015-03-12 삼성에스디아이 주식회사 편광판, 이의 제조방법 및 이를 포함하는 액정표시장치
EP3331547A4 (en) 2015-08-05 2019-08-21 Children's Medical Center Corporation COMPOSITIONS WITH PERMEATION PROMOTERS FOR ACTIVE INJECTION
EP3512501A4 (en) 2016-09-14 2020-04-29 Children's Medical Center Corporation COMPOSITIONS WITH PERMEATION AMPLIFIERS FOR MEDICATION RELEASE
US20210186943A1 (en) 2018-04-25 2021-06-24 Otonomy, Inc. Otic formulations for drug-induced ototoxicity
CA3110566A1 (en) 2018-08-31 2020-03-05 Children's Medical Center Corporation Compositions with synergistic permeation enhancers for drug delivery
US20230270749A1 (en) 2020-08-03 2023-08-31 Children's Medical Center Corporation Thermo-sensitive permeation enhancing formulations for drug delivery

Also Published As

Publication number Publication date
EP3331547A4 (en) 2019-08-21
ZA201800960B (en) 2018-12-19
PE20181153A1 (es) 2018-07-17
MX2018001571A (es) 2018-09-06
HK1252531A1 (zh) 2019-05-31
KR20180030416A (ko) 2018-03-22
US12053527B2 (en) 2024-08-06
CO2018001407A2 (es) 2018-07-19
JP2021178838A (ja) 2021-11-18
CA2994702A1 (en) 2017-02-09
CR20180128A (es) 2018-04-24
EA201890458A1 (ru) 2019-01-31
WO2017024282A1 (en) 2017-02-09
JP2018522905A (ja) 2018-08-16
JP7046793B2 (ja) 2022-04-04
ECSP18017254A (es) 2018-10-31
EP3331547A1 (en) 2018-06-13
AU2016304585B2 (en) 2023-04-06
IL257329A (en) 2018-03-29
BR112018002227A2 (pt) 2018-09-18
AU2016304585A1 (en) 2018-03-01
CN108135967B (zh) 2022-06-28
US11110175B2 (en) 2021-09-07
PH12018500262A1 (en) 2018-08-13
MA43574A (fr) 2018-11-14
US20180228903A1 (en) 2018-08-16
CN108135967A (zh) 2018-06-08
US20220040309A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2018000299A1 (es) Composiciones con potenciadores de impregnacion para el suministro de fármacos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CO2017001994A2 (es) Compuestos activos hacia bromodominios
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
CL2016002992A1 (es) Combinación, composición y método de administración de la combinación o composición a animales
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
DOP2017000156A (es) Derivados de glucagón con estabilidad mejorada
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2015002433A1 (es) Imidazopiridazinas sustituidas
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2017000394A1 (es) Composición que contiene cineol para la administración nasal
GT201700138A (es) Pirazolpiridinaminas
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
DOP2016000007A (es) Pirazolpiridinas sustituidas
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer